Cargando…

A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer

BACKGROUND: The neutrophil lymphocyte ratio (NLR) has prognostic value in patients with a variety of cancers. Many chemotherapeutic trial databases hold information on white cell and neutrophil counts only. The aim of the present study was to compare the prognostic value of the NLR with a derived sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Proctor, M J, McMillan, D C, Morrison, D S, Fletcher, C D, Horgan, P G, Clarke, S J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419948/
https://www.ncbi.nlm.nih.gov/pubmed/22828611
http://dx.doi.org/10.1038/bjc.2012.292
_version_ 1782240782918352896
author Proctor, M J
McMillan, D C
Morrison, D S
Fletcher, C D
Horgan, P G
Clarke, S J
author_facet Proctor, M J
McMillan, D C
Morrison, D S
Fletcher, C D
Horgan, P G
Clarke, S J
author_sort Proctor, M J
collection PubMed
description BACKGROUND: The neutrophil lymphocyte ratio (NLR) has prognostic value in patients with a variety of cancers. Many chemotherapeutic trial databases hold information on white cell and neutrophil counts only. The aim of the present study was to compare the prognostic value of the NLR with a derived score (dNLR), composed of white cell and neutrophil counts. METHODS: Patients (n=27 031) who were sampled incidentally between 2000 and 2007 for neutrophil, lymphocyte and white cell counts, and also had a diagnosis of cancer (Scottish Cancer Registry), were identified. Of this group, 12 118 patients who had been sampled within 2 years of their cancer diagnosis were studied. RESULTS: On follow-up, there were 7366 deaths, of which 6198 (84%) were cancer deaths. The median time from blood sampling to diagnosis was 2.1 months. The area under the receiver-operating characteristic (ROC) curve for cancer-specific survival was 0.650 for the NLR and 0.640 for the dNLR. The NLR and dNLR were independently associated with survival in all cancers studied (all P<0.001). The optimal thresholds, on the basis of hazard ratios and area under the curve, were 4 : 1 for the NLR and 2 : 1 for the dNLR. CONCLUSION: The results of the present study show that the dNLR has similar prognostic value to the NLR. Therefore, the universally available dNLR is to be commended for use in the risk stratification of patients undergoing chemotherapy.
format Online
Article
Text
id pubmed-3419948
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-34199482013-08-07 A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer Proctor, M J McMillan, D C Morrison, D S Fletcher, C D Horgan, P G Clarke, S J Br J Cancer Molecular Diagnostics BACKGROUND: The neutrophil lymphocyte ratio (NLR) has prognostic value in patients with a variety of cancers. Many chemotherapeutic trial databases hold information on white cell and neutrophil counts only. The aim of the present study was to compare the prognostic value of the NLR with a derived score (dNLR), composed of white cell and neutrophil counts. METHODS: Patients (n=27 031) who were sampled incidentally between 2000 and 2007 for neutrophil, lymphocyte and white cell counts, and also had a diagnosis of cancer (Scottish Cancer Registry), were identified. Of this group, 12 118 patients who had been sampled within 2 years of their cancer diagnosis were studied. RESULTS: On follow-up, there were 7366 deaths, of which 6198 (84%) were cancer deaths. The median time from blood sampling to diagnosis was 2.1 months. The area under the receiver-operating characteristic (ROC) curve for cancer-specific survival was 0.650 for the NLR and 0.640 for the dNLR. The NLR and dNLR were independently associated with survival in all cancers studied (all P<0.001). The optimal thresholds, on the basis of hazard ratios and area under the curve, were 4 : 1 for the NLR and 2 : 1 for the dNLR. CONCLUSION: The results of the present study show that the dNLR has similar prognostic value to the NLR. Therefore, the universally available dNLR is to be commended for use in the risk stratification of patients undergoing chemotherapy. Nature Publishing Group 2012-08-07 2012-07-24 /pmc/articles/PMC3419948/ /pubmed/22828611 http://dx.doi.org/10.1038/bjc.2012.292 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Molecular Diagnostics
Proctor, M J
McMillan, D C
Morrison, D S
Fletcher, C D
Horgan, P G
Clarke, S J
A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer
title A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer
title_full A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer
title_fullStr A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer
title_full_unstemmed A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer
title_short A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer
title_sort derived neutrophil to lymphocyte ratio predicts survival in patients with cancer
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419948/
https://www.ncbi.nlm.nih.gov/pubmed/22828611
http://dx.doi.org/10.1038/bjc.2012.292
work_keys_str_mv AT proctormj aderivedneutrophiltolymphocyteratiopredictssurvivalinpatientswithcancer
AT mcmillandc aderivedneutrophiltolymphocyteratiopredictssurvivalinpatientswithcancer
AT morrisonds aderivedneutrophiltolymphocyteratiopredictssurvivalinpatientswithcancer
AT fletchercd aderivedneutrophiltolymphocyteratiopredictssurvivalinpatientswithcancer
AT horganpg aderivedneutrophiltolymphocyteratiopredictssurvivalinpatientswithcancer
AT clarkesj aderivedneutrophiltolymphocyteratiopredictssurvivalinpatientswithcancer
AT proctormj derivedneutrophiltolymphocyteratiopredictssurvivalinpatientswithcancer
AT mcmillandc derivedneutrophiltolymphocyteratiopredictssurvivalinpatientswithcancer
AT morrisonds derivedneutrophiltolymphocyteratiopredictssurvivalinpatientswithcancer
AT fletchercd derivedneutrophiltolymphocyteratiopredictssurvivalinpatientswithcancer
AT horganpg derivedneutrophiltolymphocyteratiopredictssurvivalinpatientswithcancer
AT clarkesj derivedneutrophiltolymphocyteratiopredictssurvivalinpatientswithcancer